ArticleFrontiers in public health2025

Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for extensive-stage small cell lung cancer from the perspective of the healthcare system in China.

Feng Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.